Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PSI-697 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PSI-697 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PSI-697 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: Inclusion Criteria: * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12?lead electrocardiogram (ECG). * Smoker of at least 1 pack or more of cigarettes per day (20 plus or minus...
PSI-697 is an investigational small molecule being studied for its effects on platelets in healthy subjects who smoke. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated in a clinical trial to assess its impact on platelet function.
PSI-697 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical research on this investigational small molecule drug.
PSI-697 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied in a completed Phase 1 trial that evaluated its effects on platelets in healthy subjects who smoke.
PSI-697 has one completed clinical trial registered under NCT03860506, titled "Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke." This Phase 1 trial enrolled 30 healthy male participants and was placebo-controlled and double-blind.
PSI-697 is a small molecule drug being studied for its effects on platelets. The specific molecular target or mechanism of action has not been disclosed in available clinical trial information. The drug is being evaluated in healthy subjects who smoke to assess its impact on platelet function.